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Abstract 27 
The spread of antimicrobial resistance has become a serious public health concern, making 28 
once treatable diseases deadly again and undermining breakthrough achievements of 29 
modern medicine 1,2. Drug combinations can aid in fighting multi-drug resistant (MDR) 30 
bacterial infections, yet they are largely unexplored and rarely used in clinics. To identify 31 
general principles for antibacterial drug combinations and understand their potential, we 32 
profiled ~3,000 dose-resolved combinations of antibiotics, human-targeted drugs and food 33 
additives in 6 strains from three Gram-negative pathogens, Escherichia coli, Salmonella 34 
Typhimurium and Pseudomonas aeruginosa. Despite their phylogenetic relatedness, more 35 
than 70% of the detected drug-drug interactions are species-specific and 20% display strain 36 
specificity, revealing a large potential for narrow-spectrum therapies. Overall, antagonisms 37 
are more common than synergies and occur almost exclusively between drugs targeting 38 
different cellular processes, whereas synergies are more conserved and enriched in drugs 39 
targeting the same process. We elucidate mechanisms underlying this dichotomy and further 40 
dissect the interactions of the food additive, vanillin. Finally, we demonstrate that several 41 
synergies are effective against MDR clinical isolates in vitro and during infections of Galleria 42 
mellonella larvae, with one reverting resistance to the last-resort antibiotic, colistin.   43 
 2 
Main text 44 
To study the characteristics and conservation of drug-drug interactions in bacteria, we 45 
selected three γ-proteobacterial species, E. coli, Salmonella enterica serogroup 46 
Typhimurium, and P. aeruginosa, all belonging to the highest risk groups for antibiotic 47 
resistance 3. We used model lab strains rather than MDR isolates to derive general 48 
principles behind drug-drug interactions without being confounded by horizontally transferred 49 
antibiotic resistance elements, and to facilitate follow-up experiments and comparisons with 50 
results from others. To further assess whether drug responses vary between strains of the 51 
same species, we included two strains per species (ED Fig. 1a), probing each in up to 79 52 
compounds alone and in pairwise combinations. The compounds comprised 59% antibiotics 53 
(all major classes), 23% human-targeted drugs and food additives, most with reported 54 
antibacterial/adjuvant activity 4,5, and 18% of other compounds with known bacterial targets 55 
or genotoxic effects – e.g. proton motive force (PMF) inhibitors or oxidative damage agents, 56 
due to their potential relevance for antibiotic activity and/or uptake 6,7 (ED Fig. 1a; 57 
Supplementary Table 1). Altogether, we profiled up to 2,883 pairwise drug combinations in 58 
each of the 6 strains (17,050 in total). We assessed each drug combination in a 4x4 tailored 59 
dose matrix (Methods, Supplementary Table 1), using optical density as growth readout, and 60 
calculated fitness as the growth ratio between drug-treated and -untreated cells (ED Fig. 1-2, 61 
Methods). All experiments were done at least twice and on average 4x, with high replicate 62 
correlation (average Pearson Correlation = 0.93; ED Fig. 3a-b). 63 
 64 
We quantified all drug-drug interactions using the Bliss independence model (ED Fig. 1b, 65 
Methods). Consistent with its null hypothesis, interaction scores were zero-centered for all 66 
species (ED Fig. 3c). From all the scores (𝜀) obtained per combination (4x4 dose matrix), we 67 
derived a single interaction score 𝜀 ranging from -1 to 1 (Methods). Synergies and 68 
antagonisms were considered significant if p-value < 0.05 (Benjamini-Hochberg corrected, 69 
10,000 repetitions of a two-sided Wilcoxon rank-sum test). Strong interactions had an 70 
additional effect size requirement for |𝜀| > 0.1, whereas weak interactions could satisfy the 71 
effect size threshold for one of the two strains of the same species, but be slightly below for 72 
the other (|𝜀| > 0.06; Methods). In total we detected ~19% interactions (synergies and 73 
antagonisms) for E. coli, ~16% for S. Typhimurium, and ~11% for P. aeruginosa 74 
(Supplementary Table 2). This is in between the >70% hit rate for 21 antibiotics tested in E. 75 
coli 8 and the <2% for a larger set of combinations tested in different fungi 9. Discrepancies 76 
are likely due to: (i) drug selection biases, (ii) single drug concentrations used in previous 77 
studies (which increase false negative and positive rates), and (iii) different data analysis. 78 
For example, we observed that drugs lacking antibacterial activity engage in fewer 79 
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interactions (ED Fig. 3e). Robbins et al. screened pairwise combinations of 6 antifungals 80 
with 3,600 drugs, most of which had no antifungal activity 9, thus explaining the low number 81 
of interactions detected, whereas Yeh et al. profiled only bioactive antibiotics 8. Out of 79 82 
drugs tested here, all had at least one interaction and a median of 5-13 interactions in the 83 
different strains (ED Fig. 3f). 84 
 85 
Since drug combinations have not been systematically probed in bacteria before, we lacked 86 
a ground truth for benchmarking our dataset. To overcome this limitation, we selected 242 87 
combinations and created a validation set using higher-precision 8x8 checkerboard assays 88 
(ED Fig. 4a-b, Supplementary Table 3, Methods). We used this validation set to both assess 89 
the performance of our interaction identification approach and to benchmark our screen (ED 90 
Fig. 4c-d). Overall, we had precision and recall of 91% and 74%, respectively. The slightly 91 
lower recall can be partially explained by the larger coverage of drug concentration range in 92 
the validation experiments, which improves our ability to detect interactions (ED Fig. 5). We 93 
confirmed 90% of all weak interactions we probed in the validation set (n=46; Supplementary 94 
Table 3, ED Fig. 6), supporting the rationale of our interaction identification approach. 95 
Indeed, including weak interactions in our hits increases the recall (ED Fig. 4d). For a 96 
handful of the synergies observed between antibiotics of the same class (β-lactams), we 97 
confirmed the interactions using the Loewe additivity model (ED Fig. 4e), which is more 98 
suitable for assessing interactions between drugs with the same target.  99 
 100 
Overall, we detected 1354 antagonistic and 1230 synergistic interactions. Although this 101 
suggests that the two occur with similar frequencies, antagonisms are nearly 50% more 102 
prevalent than synergies, when correcting for the ability to detect both types of interactions 103 
(Fig. 1a). This is because we can detect antagonisms only for 75% of combinations (when at 104 
least one drug inhibits growth; ED Fig. 3d, Methods), whereas synergies are detectable for 105 
nearly all combinations. Higher prevalence of antagonisms has also been reported for 106 
antifungals 10.  107 
 108 
Strikingly, antagonisms and synergies exhibited a clear dichotomy in our data. Antagonism 109 
occurred almost exclusively between drugs targeting different cellular processes, while 110 
synergies were also abundant for drugs of the same class or targeting the same process 111 
(Fig. 1b-e, ED Fig. 7). Mechanistically, antagonism can be explained by interactions at the 112 
drug target level, with the two inhibitors helping the cell to buffer the distinct processes 113 
perturbed. DNA and protein synthesis inhibitors act this way in bacteria (Fig. 1b) 11. 114 
Consistent with this being a broader phenomenon, in genome-wide genetic interactions 115 
studies in yeast, alleviating interactions (antagonisms) are enriched between essential 116 
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genes (the targets of anti-infectives), which are part of different functional processes 12. 117 
However, antagonism can also occur at the level of intracellular drug concentrations (ED 118 
Fig. 8a). We tested 16 antagonistic interactions of different drugs with gentamicin or 119 
ciprofloxacin in E. coli to investigate to what extent this occurs. Although initially detected at 120 
a growth inhibition level, all antagonisms held true at a killing level, with 14/16 decreasing 121 
the intracellular gentamicin or ciprofloxacin concentrations (ED Fig. 8b). In several cases 122 
tested, this likely occurred because the second drug decreased the PMF-energized uptake 123 
of gentamicin or increased AcrAB-TolC-dependent efflux of ciprofloxacin, as antagonisms 124 
were neutralized in the respective mutant backgrounds (ED Fig. 8c). Overall, our results 125 
suggest that a large fraction of antagonisms is due to modulation of intracellular drug 126 
concentrations, rather than due to direct interactions of the primary drug targets (ED Fig. 8d-127 
e). 128 
 129 
Unlike antagonistic interactions, synergies often occurred between drugs targeting the same 130 
cellular process (Fig. 1b-e, ED Fig. 7). In fact, synergies are significantly enriched within 131 
drugs of the same category across all three species (p-value < 10-16, Fisher’s exact test), 132 
given that there are ~15-fold more possible drug combinations across than within drug 133 
categories in our dataset. Mechanistically, targeting the same functional process at different 134 
steps could bypass its redundancy. For example, β-lactams have different affinities to the 135 
numerous and often redundant penicillin-binding-proteins (PBPs), likely explaining the many 136 
synergies between them (Fig. 1b, ED Fig. 4e & 7a-b).  137 
 138 
Like antagonisms, synergies can also occur due to modulation of intracellular drug 139 
concentrations. Consistent with a general permeabilization role of membrane-targeting 140 
compounds in many organisms 9,13,14, and with drug uptake being a major bottleneck for 141 
Gram-negative pathogens, one fourth of all detected synergies contain at least one out of 142 
eight membrane-targeting drugs in our screen (two-sided Wilcoxon rank-sum test, p-143 
value=0.06). However, membrane-targeting compounds account also for ~18% of 144 
antagonisms, suggesting that perturbations in membrane integrity can also decrease 145 
intracellular drug concentrations. Consistently, benzalkonium decreases the intracellular 146 
concentration of both gentamicin and ciprofloxacin, likely by interfering with their active 147 
import in the cell (ED Fig. 8b-c).  148 
 149 
We next examined the conservation of drug-drug interactions. Interactions within species 150 
were highly conserved (Fig. 2a, ED Fig. 9a-b): 53-76%, depending on the species (Fig. 2b). 151 
Conservation is actually higher (68-87%, and on average 80%), if we disregard the non-152 
comparable interactions for which the concentration range tested preclude us from detecting 153 
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synergy or antagonism for both strains (Fig. 2b, ED Fig. 3d). High conservation of drug-drug 154 
interactions within species is consistent with the finding that such interactions are generally 155 
robust to simple genetic perturbations 15. Despite this high-degree conservation within 156 
species, 13-32% of the interactions remained strain-specific, with the majority being neutral 157 
in the second strain. Very few drug combinations synergized for one strain and antagonized 158 
for the other (16 interactions), but such strain differences held in our validation set 159 
(Supplementary Table 2).  160 
 161 
While conservation is relatively high within species, it is very low across species (Fig. 2c, ED 162 
Fig. 9c). The majority (70%) of interactions occurred in one species, and only 5% were 163 
conserved in all three phylogenetically close-related species. Since conservation is much 164 
higher at the single-drug level for the three species (sharing resistance/sensitivity to 73% of 165 
the drugs; Supplementary Table 1, Methods), this indicates that drug combinations can 166 
impart species specificity to the drug action. Such specificities can be beneficial for creating 167 
narrow spectrum therapies with low collateral damage, by using synergies specific for 168 
pathogens and antagonisms specific for abundant commensals. 169 
 170 
Moreover, we found that synergies are significantly more conserved than antagonisms (Fig. 171 
2d), despite being less prevalent (Fig. 1a). This is presumably because: i) synergies are 172 
enriched between drugs of the same category, and interactions within functional processes 173 
are conserved across evolution 16; ii) membrane-targeting drugs have a general potentiation 174 
effect in Gram-negative bacteria; and iii) antagonisms often depend on drug import/uptake 175 
(ED Fig. 8), which are controlled by less conserved envelope machineries. 176 
 177 
Exploring the network of conserved drug-drug interactions across the three species (ED Fig. 178 
9d) exposed potential Achilles heels of Gram-negative bacteria, such as the strong synergy 179 
of colistin with macrolides 17, but also revealed that known antibiotic classes often behave 180 
non-uniformly. For example, the well-known synergy between β-lactams and 181 
aminoglycosides is confined to potent aminoglycosides used in our screen (amikacin and 182 
tobramycin) and β-lactams that target specifically the cell-division related PBPs (piperacillin, 183 
aztreonam, cefotaxime), in agreement with previous reports 18. To address whether pairwise 184 
drug interactions are Mode of Action (MoA)-driven (i.e. drug classes interacting purely 185 
synergistic or antagonistic with each other) 8, we calculated a monochromaticity index (MI) 186 
for all drug category pairs, across all species (Methods). For highly monochromatic category 187 
pairs, MI approaches 1 and -1 for antagonism and synergy, respectively. MI is overall high, 188 
especially between well-defined antibiotic classes. Yet, a number of them, including β-189 
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lactams, tetracyclines and macrolides, have mixed antagonisms and synergies with other 190 
antibiotic classes (ED Fig. 9e). While β-lactams have diverse affinities to their multiple PBP 191 
targets (potentially explaining the mixed interactions with other classes), the same does not 192 
apply to protein synthesis inhibitors, which have unique targets. In this case, non-uniform 193 
class behavior may be due to different chemical properties of the class members, and thus 194 
different dependencies on uptake and efflux systems. Aggregating the MI per drug category 195 
reinforced the view that broader categories exhibit less concordant interactions (ED Fig. 9f). 196 
Besides membrane targeting drugs, human-targeted drugs were the category exhibiting the 197 
most synergies, suggesting that many may act as adjuvants. 198 
 199 
Since antibiotic classes interacted largely monochromatically, clustering drugs according to 200 
their interactions recapitulated the class groupings (ED Fig. 10). For example, cell-wall 201 
inhibitors grouped together, with further subdivisions being reflective of target specificity. 202 
Yet, exceptions were also evident, such as the macrolides, which split. Azithromycin, the 203 
only dibasic macrolide separates from its class co-members and clusters with two other 204 
basic antibiotics, bleomycin and phleomycin. Azithromycin interacts with and crosses the 205 
outer membrane (OM) of Gram-negative bacteria distinctly to other macrolides 17,19, and has 206 
also different binding kinetics to the peptide exit tunnel of the 50S ribosomal subunit 20. For 207 
drugs with unknown or less-well defined targets, clustering hinted towards possible MoA’s. 208 
Among them, we selected the flavoring compound vanillin, which clusters together with the 209 
structurally related acetylsalicylic acid (aspirin). Salicylate and aspirin induce the expression 210 
of the major efflux pump in enterobacteria, AcrAB-TolC via binding and inactivating the 211 
transcriptional repressor MarR 21 (Fig. 3a). Consistent with a similar action, vanillin treatment 212 
increased AcrA protein levels in E. coli, due to marA overexpression (Fig. 3b-c). Higher AcrA 213 
levels upon vanillin or aspirin treatment led to higher chloramphenicol and ciprofloxacin 214 
MICs (Fig. 3d-e). As previously reported for salicylate 22, vanillin exerts an additional minor 215 
effect on drug resistance in a MarR/A-independent manner, presumably via the MarA 216 
homologue, Rob (Fig. 3c-e).   217 
 218 
To test whether detected interactions are relevant for resistant isolates, we selected seven 219 
strong and conserved synergies, comprising antibiotics, human-targeted drugs or food 220 
additives, and assessed their efficacy against six MDR and XDR E. coli and Klebsiella 221 
pneumoniae clinical isolates. All strains were recovered from infected patients, belonging to 222 
successfully spread clonal lineages harboring extended spectrum β-lactamase (ESBL) 223 
resistance and various highly prevalent carbapenemases  23,24. One K. pneumoniae strain 224 
(929) is also resistant to the last-resort antibiotic, colistin, due to a chromosomal mutation 225 
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(Supplementary Table 4). All drug pairs acted synergistically in most of the strains tested 226 
(Fig. 4a, ED Fig. 11a). We further tested colistin-clarithromycin and spectinomycin-vanillin, 227 
with an established infection model for evaluating antibacterial activity, using larvae the 228 
greater wax moth, Galleria mellonella. Both combinations also acted synergistically in vivo 229 
by increasing G. mellonella survival during infection (Fig. 4b & ED Fig. 11b).  230 
 231 
The strongest of these synergies is between colistin and different macrolides (Fig. 4, ED Fig. 232 
11). Although other polymyxins are known to help macrolides cross the OM of Gram-233 
negative bacteria 17, this particular synergy occurred at low colistin concentration (< 0.3 234 
µg/ml) and was active even for the intrinsically colistin-resistant strain (Fig. 4, K. pneumoniae 235 
929), implying that macrolides may also potentiate colistin via a yet unknown mechanism. 236 
Similar resensitization of colistin-resistant pathogens to colistin by macrolides was recently 237 
reported for plasmid-borne colistin resistance 25, indicating that this synergy is independent 238 
of the resistance mechanism. In addition to antibiotic pairs, combinations of human-targeted 239 
drugs or food additives with antibiotics were also effective against MDR isolates, even when 240 
the former lacked antibacterial activity on their own (ED Fig. 11).  241 
 242 
Finally, vanillin potentiated the activity of spectinomycin in E. coli MDR isolates. This was 243 
intriguing, since vanillin antagonizes many other drugs, including other aminoglycosides 244 
(Supplementary Table 2). We confirmed that this interaction is specific to spectinomycin and 245 
vanillin, and not to other aminoglycosides or aspirin, and thus independent of the vanillin 246 
effect on AcrAB-TolC (ED Fig. 12a-c). We then probed a genome-wide E. coli gene 247 
knockout library 26 to identify mutants that abrogate the vanillin-spectinomycin interaction, 248 
but do not influence the amikacin (another aminoglycoside)-vanillin interaction. One of the 249 
top hits was mdfA, which encodes for a Major Facilitator Superfamily transporter, exporting 250 
both charged and neutral compounds 27 (ED Fig. 12c). Consistent with MdfA modulating 251 
spectinomycin uptake, ΔmdfA cells were more resistant to spectinomycin and not responsive 252 
to vanillin (ED Fig. 12d), whereas cells overexpressing mdfA were more sensitive to 253 
spectinomycin (ED Fig. 12e, not visible at the MIC level in ED Fig. 12d), as previously 254 
reported 28, with vanillin further exacerbating this effect (ED Fig. 12d). Vanillin addition also 255 
increased the intracellular spectinomycin concentration in an mdfA-dependent manner (ED 256 
Fig. 12e). At this point, it is unclear how MdfA, which is known to export compounds out of 257 
the cell, facilitates spectinomycin import in the cell. However, the phylogenetic occurrence of 258 
mdfA is concordant with the species-specificity of this interaction, as we detected the 259 
synergy in E. coli and S. Typhimurium, but not in the phylogenetically more distant, P. 260 
aeruginosa and K. pneumoniae isolates, which lack mdfA. This synergy underlines the 261 
importance of exploring the role of food additives in combinatorial therapies 5. 262 
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 263 
In summary, we generated a comprehensive resource of pairwise drug combinations in 264 
Gram-negative bacteria, illuminating key principles of drug-drug interactions and providing a 265 
framework for assessing their conservation across organisms or individuals (Supplementary 266 
Discussion). Such information can nucleate similar screens in other microbes, studies 267 
investigating the underlying mechanism of pairwise drug combinations 11,15,29 and 268 
computational predictions of their outcomes 30,31. Some of the herein identified principles 269 
may go beyond anti-infectives and microbes 32. For antibacterial drug therapies, our study 270 
highlights the promise that non-antibiotic drugs hold as adjuvants, offers a new path for 271 
narrow spectrum therapies and identifies effective synergies against MDR clinical isolates 272 
(Supplementary Discussion). Further experimentation is required to address whether such 273 
synergies have clinical relevance.       274 
 275 
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Figure legends 296 
Figure 1: Principles of drug-drug interaction networks. a) Antagonism is more prevalent 297 
than synergy. Fraction of observed over detectable interactions for the 6 strains. We detect 298 
more antagonistic (1354) than synergistic (1230) interactions, although our ability to detect 299 
antagonisms is lower than synergy: 12,778 versus 16,920 combinations. b & d) Drug-drug 300 
interaction networks in E. coli. Nodes represent either drug categories (b) or drugs grouped 301 
according to the general cellular process they target (d). Node color is as ED Fig. 1a and 302 
node size reflects the number of drugs within category. Edges represent synergy (blue) and 303 
antagonism (orange); thickness reflects number of interactions. Interactions between drugs 304 
of the same category/general cellular target are represented by self-interacting edges. 305 
Conserved interactions, including weak, are shown. c & e) Antagonisms occur almost 306 
exclusively between drugs belonging to different categories (c) or targeting different cellular 307 
processes (e), whereas synergies are also abundant between drugs within the same 308 
category (c) or targeting the same process (e). Quantification and Chi-squared test p-values 309 
from E. coli drug-drug interactions are shown in b and d, respectively.  310 
 311 
Figure 2: Drug-drug interaction conservation. a) Drug-drug interactions are conserved in 312 
E. coli. Scatter plot of interaction scores from the two E. coli strains; significant interactions 313 
for at least one of the strains are shown. Dark blue: strong and conserved interactions in 314 
both strains; light blue: strong interactions in one strain and concordant behavior in other 315 
(weak and conserved); grey: interactions occurring exclusively in one strain or conflicting 316 
between strains (non-conserved). R denotes the Pearson correlation, n the number 317 
interactions plotted. b) Drug-drug interactions are highly conserved within species. Colors as 318 
in a; non-comparable refers to combinations that have significantly different single drug dose 319 
responses between strains (Methods). c) Drug-drug interactions are largely species-specific; 320 
n = total number of interactions; nc = conflicting interactions between species, not accounted 321 
for in Venn diagram. d) Synergies are more conserved than antagonisms. Mosaic plots and 322 
Chi-squared test p-values show the quantification of synergy and antagonism among 323 
conserved (fully and partially) and non-conserved interactions between species.  324 
 325 
Figure 3: Vanillin induces a multi-antibiotic-resistance (mar) phenotype. a) Vanillin and 326 
aspirin (acetylsalicylic acid) have similar drug-drug interaction profiles (see ED Fig. 10), 327 
suggesting similar MoA’s. A schematic representation of the mar response induction via 328 
deactivation of the MarR repressor by salicylate/aspirin 21 is illustrated. b) Vanillin increases 329 
AcrA levels in a marA-dependent manner. A representative immunoblot of exponentially 330 
growing cells (all blots shown in Supplementary Fig. 1) after treatment with solvent, vanillin 331 
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(150µg/ml) or aspirin (500µg/ml) is shown - loading controlled by cell density and 332 
constitutively expressed RecA. Barplots depict AcrA protein level quantification; c) marA 333 
expression levels upon vanillin (150µg/ml) or aspirin (500µg/ml) treatment are stronger in 334 
wildtype than in ΔmarR mutant. Expression is measured by RT-qPCR and normalized to no-335 
drug treatment in wildtype; d & e) Vanillin (150 µg/ml) and aspirin (500µg/ml) increase the 336 
MIC of chloramphenicol (d) or ciprofloxacin (e). Antagonism is weaker and abolished in 337 
ΔmarA and ΔacrA mutants, respectively. n = number of independent biological replicates 338 
and error bars depict standard deviation (b-e). 339 
 340 
Figure 4: Potent synergistic combinations against Gram-negative MDR clinical 341 
isolates. a) In vitro synergies, shown as 8x8 checkerboards, for 3 MDR strains (more strains 342 
and synergies in ED Fig. 11). One of two biological replicates is shown. b) Drug synergies 343 
against the same MDR strains in the Galleria mellonella infection model (see also ED Fig. 344 
11). Larvae were infected by E. coli and K. pneumoniae MDR isolates (106 and 104 CFU, 345 
respectively) and left untreated, or treated with single drugs or combination. % larvae 346 
survival was monitored at indicated intervals after infection – n=10 larvae per treatment. The 347 
average of 4 biological replicates are shown; error bars depict standard deviation. 348 
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Methods 425 
Strains, plasmids and drugs 426 
For each of the three Gram-negative species profiled in this study, we used two common 427 
sequenced lab strains for each species: Escherichia coli K-12 BW25113 and O8 IAI1, 428 
Salmonella enterica serovar Typhimurium LT2 and 14028s, Pseudomonas aeruginosa 429 
PAO1 and PA14. To validate selected synergies, we profiled 6 MDR clinical 430 
Enterobacteriaceae isolates recovered from human patient specimens: E. coli 124, 1027, 431 
1334 and Klebsiella pneumoniae 718, 929 and 980 (see Supplementary Table 4 for details 432 
on antibiotic resistance determinants). For follow-up experiments, we used two closely-433 
related E. coli K-12 model strains, BW25113 and MG1655. 434 
 435 
All mutants used in this study were made using the E. coli Keio Knockout Collection 26 - after 436 
PCR-confirming and retransducing the mutation to wildtype BW25113 with the P1 phage 437 
(Supplementary Table 5). The kanamycin resistance cassette was excised when necessary 438 
using the plasmid pCP20 33. The plasmid used for mdfA overexpression was obtained from 439 
the mobile E. coli ORF library 34. 440 
 441 
Drugs used in this study were purchased from Sigma Aldrich, except for metformin 442 
hydrochloride (TCI Chemicals), clindamycin and bleomycin (Applichem), CHIR-090 443 
(MedChemtronica) and vanillin (Roth). Stocks were prepared according to supplier 444 
recommendations (preferably dissolved in water).  445 
 446 
Minimal Inhibitory Concentration (MIC) calculation 447 
We defined MIC as the lowest concentration required to inhibit growth of a microorganism 448 
after 8 hours of incubation in Lysogeny Broth (LB) at 37oC with shaking (384 wells plates, 449 
starting OD595nm 0.01). MICs of all drugs were computed using a logistic fit of growth 450 
(OD595nm for 8h) over 2-fold serial dilutions of the antibiotic concentrations for all strains used 451 
for the high-throughput screening and follow-up experiments. 452 
 453 
High-throughput screening of pairwise drug interactions 454 
For all drug combination experiments, drugs were diluted in LB to the appropriate working 455 
concentrations in transparent 384-well plates (Greiner BioOne GmbH), with each well 456 
containing 30µl in total. After the addition of drugs, cells were inoculated at initial OD595nm 457 
~0.01 from an overnight culture. The same inoculum was used for all strains. All liquid 458 
handling (drug addition, cell mixing) was done with a Biomek FX liquid handler (Beckman 459 
Coulter). Plates were sealed with breathable membranes (Breathe-Easy®) and incubated at 460 
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37oC in a humidity-saturated incubator (Cytomat 2, Thermo Scientific) with continuous 461 
shaking and without lids to avoid condensation. OD595nm was measured every 40 min for 12 462 
hours in a Filtermax F5 multimode plate reader (Molecular Devices). 463 
 464 
A flowchart of the experimental and analytical pipeline is shown in ED Fig. 2a. Data analysis 465 
was implemented with R and networks were created with Cytoscape 35. 466 
 467 
Experimental Pipeline 468 
The drug-drug interaction screen was performed using 4x4 checkerboards. 62 drugs were 469 
arrayed in 384 well plates with the different concentrations in duplicates (array drugs). Each 470 
plate contained 12 randomly distributed wells without arrayed drug: 9 wells containing only 471 
the query drug, and 3 wells without any drug. One query drug at a single concentration was 472 
added in all wells of the 384-well plate, except for the 3 control wells. All drugs were queried 473 
once per concentration, occasionally twice. We used 78 drugs as query in E. coli and S. 474 
Typhimurium, and 76 in P. aeruginosa. In total 79 query drugs were screened, out of which 475 
75 were common for all three species (Supplementary Table 1). The 62 array drugs were a 476 
subset of the 79 query drugs. The same drug concentrations were used in both query and 477 
array drugs (Supplementary Table 1). Three drug concentrations (2-fold dilution series) were 478 
selected based on the MIC curves, tailored to the strain and drug. We targeted for nearly full, 479 
moderate, and mild/no growth inhibition –on average, corresponding to 50-100%, 25-50% 480 
and 0-25% of the MIC, respectively. The highest drug concentration and the lowest fitness 481 
obtained per single drug are listed in Supplementary Table 1. For drugs that do not inhibit 482 
growth on their own, we selected concentrations according to sensitivity of other 483 
strains/species or to their use in clinics or for research. E. coli and S. Typhimurium exhibited 484 
largely similar single drug dose responses within species, thus the same drug 485 
concentrations were used for both strains of each species. For P. aeruginosa, MICs often 486 
differed by several fold, thus drug concentrations were adjusted between the two strains 487 
(Supplementary Table 1). 488 
 489 
Growth curves analysis 490 
The Gompertz model was fitted to all growth curves (when growth was observed) by using 491 
the R package grofit version 1.1.1-1 for noise reduction. Quality of fit was assessed by 492 
Pearson correlation (R), which was > 0.95 for ~95% of all growth curves. R < 0.95 was 493 
indicative of either non-sigmoidal-shaped growth curves, typical of some drugs such as 494 
fosfomycin, or noisy data. In the former case, the original data was kept for further analysis. 495 
In the latter case, noisy data was removed from further analysis. Plate effects were 496 
corrected by fitting a polynomial to the median growth of each row and column. Background 497 
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signal from LB was removed by subtracting the median curve of the non-growing wells from 498 
the same plate. These were wells in which either the single or the double drug treatments 499 
fully inhibited growth; each plate contained at least three such wells. Data was processed 500 
per strain and per batch to correct for systematic effects. 501 
 502 
Fitness estimation 503 
We used a single time-point OD595nm measurement (growth) for assessing fitness. This 504 
corresponded to the transition to stationary phase for cells grown without perturbation, as 505 
this allows us to capture the effect of drugs on lag-phase, growth rate or maximum growth. 506 
Thus, we used OD595nm at 8 hours for E. coli BW25113 and both P. aeruginosa strains, at 7 507 
hours for the fast-growers E. coli iAi1 and S. Typhimurium 14028s, and at 9 hours for the 508 
slower growing S. Typhimurium LT2. 509 
 510 
We used the Bliss model to assess interactions, as it can accommodate drugs that have no 511 
effect alone, but potentiate the activity of others (adjuvants) 36. This feature is especially 512 
relevant here, since we probed intrinsically antibiotic-resistant microbes (P. aeruginosa and 513 
MDR clinical isolates), and human-targeted drugs or food additives lacking antibacterial 514 
activity. According to the Bliss independence model 37 and assuming that drug-drug 515 
interactions are rare, for most drug combinations the fitness of arrayed drugs (fa) equals the 516 
fitness in the presence of both drugs (faq) divided by the fitness of the query drug alone (fq): 517 
                  𝜀 = 𝑓!" − 𝑓! ∗ 𝑓!             (Eq. 1)  518 
if 𝜀 = 0 519 
                   𝑓! = !!"!! ⟺ 𝑓! = !!" !!!! !! ⟺ 𝑓! = !!"!!         (Eq. 2) 520 
where 𝜀 denotes the Bliss score, f denotes fitness, g denotes growth, a denotes an arrayed 521 
drug, q denotes a query drug and 0 denotes no drug. The fitness in the presence of both 522 
drugs (faq) was calculated by dividing the growth in the presence of both drugs (gaq) by the 523 
median of the growth of drug-free wells from the same plate (g0). The fitness of the single 524 
query drugs (fq) was obtained by dividing the top 5% growing wells across each batch by the 525 
median of the growth of drug-free wells of each plate (g0). This metric is more robust to 526 
experimental errors than using only the 9 wells containing the query drug alone. 527 
Nevertheless, both estimators for fq yield very similar results (Pearson correlation = 0.98). In 528 
line with Eq. 2, the fitness of arrayed drugs (fa) was estimated by the slope of the line of best 529 
fit between gaq and gq across all plates (query drugs) within a batch:  530 𝑔!!⋮𝑔!! !×! ∙ 𝑓!! =
𝑔!!!!⋮𝑔!!!! !×!, 1 ≤ 𝑚 ≤ 𝑛𝑟 𝑎𝑟𝑟𝑎𝑦𝑒𝑑 𝑑𝑟𝑢𝑔𝑠    (Eq. 3) 531 
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for given array drug m (am) across n query drugs q within a batch (ED Fig. 2b). 532 
 533 
For array drugs with Pearson correlation between gaq and gq below 0.7, fa was estimated 534 
using only the query drugs corresponding to the interquartile range of gaq/gq (minimum n = 535 
18 query drugs, ED Fig. 2b). Wells where r was still below 0.7, even after restricting the 536 
number of plates, were removed from further analysis due to high noise (~2%). For wells 537 
exhibiting no growth for > 75% of the plates within a batch fa was deemed as zero. 538 
 539 
Interaction scores 540 
Bliss independence 541 
Bliss scores (𝜀) were calculated for each well as described above (Eq. 1). At least 3 x 3 drug 542 
concentrations x 2 (duplicates) x 2 (query and array drugs) = 36, or 18 (drugs used only as 543 
query) scores were obtained per drug pair. Drug-drug interactions were inferred based on 544 
the Bliss independence model in three steps: a) strong interactions based on complete 𝜀 545 
distributions, b) strong interactions based on 𝜀 distributions restricted to relevant drug 546 
concentrations and c) weak and conserved interactions within species. Cross-species 547 
comparison, drug-drug interaction networks and monochromaticity analysis shown in this 548 
study include all drug-drug interactions. 549 
 550 
a) Strong drug-drug interactions based on complete 𝜀 distributions 551 
Strong drug-drug interactions were statistically assigned using a re-sampling approach. 552 
10,000 repetitions of a two-sided Wilcoxon rank-sum test (per drug pair, per strain) were 553 
performed, in order to sample a representative set of 𝜀 for a given strain. For every 554 
repetition, the 𝜀 distribution of a given combination was compared to a 𝜀 distribution of the 555 
same size randomly sampled from the complete 𝜀 set for a given strain. P-values were 556 
calculated as follows: 557 𝑝 =  (𝑝! > 0.1)!!!! + 1𝑁 + 1           (Eq. 4) 
where N is the total number of repetitions (10,000) and pn is the p-value of the Wilcoxon 558 
rank-sum test obtained for the nth repetition. Strong drug-drug interactions were assigned to 559 
those drug pairs simultaneously satisfying two criteria: i) 1st or 3rd quartile of the 𝜀 distribution 560 
below -0.1 or higher than 0.1, for synergies or antagonisms respectively, and ii) p < 0.05 561 
(after correcting for multiple testing, Benjamini-Hochberg). Only one-sided drug interactions 562 
were taken into account, thus those very few interactions satisfying the criteria concurrently 563 
for synergy and antagonism were re-assigned as neutral (only n=1 for 𝜀 > |0.1|). The highest 564 
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absolute 𝜀 value between 1st and 3rd quartile was used as single interaction score (𝜀) to 565 
reflect the strength of the drug-drug interactions. 566 
 567 
b) Strong drug-drug interactions based on 𝜀 distributions restricted to relevant drug 568 
concentrations 569 
Because drug interactions are concentration dependent, the same statistical procedure was 570 
repeated after restricting the drug concentration ratios to those relevant for either synergy or 571 
antagonism. This constraint was added by excluding 𝜀 values corresponding to 572 
concentration ratios where the expected fitness (product of the fitness on single drugs, fa*fb) 573 
was below 0.2 for synergy and above 0.8 for antagonism – blind spots for either interaction 574 
type (ED Fig. 3d). These interactions are described by their p-value and 𝜀 obtained with 575 
restricted drug concentration ratios. Although most interactions were detected based on both 576 
full and restricted 𝜀 distributions, each of the different methods uniquely identified 577 
interactions (ED Fig. 4c). With the expected fitness cutoff of 0.2, we identified the highest 578 
number of strong interactions (1950) with 90 uniquely identified interactions from full 𝜀 579 
distributions and 379 from restricted (see also sensitivity analysis section in methods).   580 
 581 
Restricting 𝜀 values based on expected fitness also allows defining whether synergy or 582 
antagonism is detectable for any given drug pair. No significant p-value was found for drug 583 
pairs with less than 5 𝜀 scores within the relevant expected fitness space, as their sample 584 
size is insufficient. Synergy and antagonism could not be detected for 1% and 25% of all 585 
drug combinations, respectively. 586 
 587 
c) Weak and conserved drug-drug interactions within species 588 
For drug pairs with a strong drug-drug interaction in only one of the two strains per species, 589 
the criteria for assigning interactions for the second strain was relaxed to |𝜀!"#$%& !"#$%&| > 590 
0.06, provided that the interaction sign was the same. Interactions assigned with this 591 
approach are termed weak and conserved. 592 
 593 
Loewe Additivity 594 
For combinations between β-lactams for which high-resolution 8x8 checkerboards with 595 
sufficient growth inhibition was available in the validation dataset, Loewe additivity 38 was 596 
used to confirm the interactions. Drug-drug interactions were inferred by the shape of the 597 
isoboles (lines of equal growth) in two-dimensional drug concentration plots. Unless stated 598 
otherwise, all isoboles correspond to 50% growth inhibition (IC50) and were obtained by 599 
fitting a logistic model – with lines representing isoboles and dots IC50 interpolated 600 
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concentrations. To interpolate IC50 concentrations (or other ICn%), a logistic model was used 601 
to fit the growth for each concentration of the first drug across different concentrations of the 602 
second drug. The null-hypothesis of this model is represented by the additivity line: a linear 603 
isobole connecting equal individual IC’s of the two drugs. 604 
 605 
Sensitivity analysis 606 
We confirmed the adequacy of the main statistical parameters used to assign interactions by 607 
performing a sensitivity analysis. Several expected fitness (fa*fb) cutoffs were tested, while 608 
keeping the other parameters constant (ED Fig. 4c). The added value of restricting the ε 609 
distributions to relevant drug concentrations (based on expected fitness) was strongly 610 
supported by the proportion of strong drug-drug interactions found exclusively using this 611 
criterion (~19% with our selected cutoff). The selected cutoff (0.2; disregarding wells with 612 
fa*fb < 0.2 for synergies and with fa*fb > 0.8 for antagonisms) resulted in the largest number of 613 
total interactions assigned, and the highest precision (91%) and recall (74%) after 614 
benchmarking against the validation dataset (ED Fig. 4c). 615 
 616 
The suitability of the thresholds applied to define strong (| 𝜀 | > 0.1) and weak (| 𝜀 | > 0.06) 617 
interactions was assessed by their impact on the true and false positive rates (TPR and FPR 618 
respectively, ED Fig. 4d). A threshold of | 𝜀 | > 0.1 is beneficial, as it imposes a minimum 619 
strength to assign interactions. 0.1 corresponds to ~3 times the median of the 1st and 3rd 620 
quartiles across all 𝜀 distributions (ED Fig. 2c). Lowering this threshold results in lower TPR, 621 
because several drug pairs are reassigned to neutral due to ambiguity in calling interaction 622 
(we do not allow interactions to be both a synergy and an antagonism). Increasing this 623 
threshold lowers the TPR, because only very strong interactions will be assigned (ED Fig. 624 
4d). Drug-drug interactions are highly conserved within species, exhibiting high correlation of 625 𝜀 observed for all species (Fig. 2a and ED Fig. 9a-b). This motivated us to relax the 626 
interaction strength threshold for the second strain if the interaction score | 𝜀 | was above 0.1 627 
in the first strain, dubbing these interactions weak and conserved. Including weak and 628 
conserved interactions in our analysis increased the TPR by 15%. Adding a threshold for 629 
weak interactions of | 𝜀 | > 0.06 (~2 times the median of the 1st and 3rd quartiles of all 𝜀 630 
distributions) is key for maintaining low FPR (ED Fig. 4d). 631 
 632 
Benchmarking & clinical isolates checkerboard assays 633 
8x8 checkerboard assays were performed for validating our screen (242 drug combinations - 634 
benchmarking dataset, Supplementary Table 3), as well as to test 7 selected synergies 635 
against 6 MDR clinical isolates (Fig. 4 & ED Fig. 11). As in the screen, growth was assessed 636 
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based on OD595nm at the transition to stationary phase for the no drug controls. The 637 
timepoints used in the screen were used again for the validation set, whereas 8 hours were 638 
used for all E. coli and K. pneumoniae MDR isolates. Fitness was calculated by dividing 639 
OD595nm after single or double drug treatment by no drug treatment for each individual 640 
checkerboard. Bliss scores (𝜀) were calculated as before, resulting in 49 𝜀 values per drug 641 
pair. Drug combinations were analyzed based on 𝜀 distributions, after removing wells in 642 
which one of the drugs alone and its subsequent combinations with the second drug 643 
completely inhibited growth. Antagonism was assigned when the median of the 𝜀 distribution 644 
was above 0.1 or the 3rd quartile was above 0.15. Similarly, synergies were assigned when 645 
the median of the 𝜀 distribution was below -0.1 or the 1st quartile was below -0.15. All 646 
experiments were done in biological duplicates, and interactions were considered effective 647 
when duplicates were consistent (vast majority of cases). 648 
 649 
Assessing conservation of drug-drug interactions 650 
Conservation of drug-drug interactions between strains of the same species was assessed 651 
by Pearson correlation of the interactions scores, 𝜀. For potentially non-conserved drug-drug 652 
interactions, the expected fitness distributions of the two strains were taken into account. 653 
When the two distributions were significantly different according to a two-sided Wilcoxon 654 
rank-sum test (p-value < 0.05 after BH correction for multiple testing), the drug pairs were 655 
deemed as non-comparable between the two strains. 656 
 657 
To assess the cross-species conservation of drug-drug interactions, we took into account 658 
only drug pairs that were probed in all three species. Drug-drug interactions were defined as 659 
being detected within a species, when detected in at least one of the two strains and no 660 
change of interaction sign was observed for the other strain. Interactions were then 661 
compared across the three species. Cases in which an interaction between drugs changed 662 
from synergy to antagonism or vice versa across species (conflicting interactions; ~7% of all 663 
interactions -Supplementary Table 2) were excluded from the comparative “across-species” 664 
Venn diagram (Fig. 2c). Note that with current analysis a given drug-drug interaction may be 665 
conserved across species, but not conserved within the species. 666 
 667 
Conservation at the single drug level was defined based on shared resistance and sensitivity 668 
(Supplementary Table 1). A strain was considered sensitive to a given drug if one of the 669 
drug concentrations resulted in at least 30% growth inhibition. In line with conservation of 670 
drug-drug interactions across species, single drug responses are conserved across species 671 
when at least one strain of both species has the same sign (sensitive or resistant). 672 
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 673 
Monochromaticity index 674 
The monochromaticity index (MI) between drug pairs was defined as in Szappanos et al. 39:  675 
 676 𝑖𝑓 𝑟!" > 𝑏,𝑀𝐼!" = 𝑟!" − 𝑏1 − 𝑏  
                                          𝑓𝑖 𝑟!" = 𝑏,𝑀𝐼!" = 0             (𝐸𝑞. 5) 677 𝑖𝑓 𝑟!" < 𝑏,𝑀𝐼!" = 𝑟!" − 𝑏𝑏  
where rij denotes the ratio of antagonism to all interactions between drugs from classes i and 678 
j, and b denotes the ratio of antagonism to all interactions. We set a minimum of 2 679 
interactions between drugs from classes i and j in order to calculate the MI. MI equals 1 if 680 
only antagonisms occur between drugs from classes i and j, and -1 if only synergies occur. 681 
MI equals zero if the fraction of antagonism reflects the background ratio b. Both strong and 682 
weak drug interactions were taken into account across all species, in order to obtain one MI 683 
index per drug category pair. 684 
 685 
Assessment of drug combinations in the Galleria mellonella infection model 686 
Larvae of the greater wax moth (Galleria mellonella) at their final instar larval stage were 687 
used as an in vivo model to assess efficacy of drug combinations. Larvae were purchased 688 
from UK Waxworms (Sheffield, UK) and TZ-Terraristik (Cloppenburg, Germany). Stock 689 
solutions of vanillin (in 20% DMSO), spectinomycin, colistin and clarithromycin (20% 690 
DMSO/0.01% glacial acetic acid) were freshly prepared and diluted in PBS to the required 691 
concentration. Drugs and bacterial suspensions were administered by injection of 10 µL 692 
aliquots into the hemocoel via the last left (drugs) and right (antibiotic) proleg using Hamilton 693 
precision syringes. Controls included both uninfected larvae, and larvae which were injected 694 
into both last prolegs with the solvent used for the drugs. Drug toxicity was pre-evaluated by 695 
injection of serial dilutions of either single drugs or drug combination, and drugs were used 696 
at amounts that caused little/no toxicity. To identify an optimal inoculum, time-kill curves 697 
were generated by inoculating larvae with 10 µl of serial diluted bacterial suspensions (1x102 698 
to 1x107 colony forming units [CFU]).  For final experiments, groups of ten larvae were 699 
injected per strain/drug combination and placed into Petri dishes and incubated at 37 °C. 700 
Larvae were infected with a sublethal dose of 106 and 104 CFU for E. coli and K. 701 
pneumoniae isolates, respectively, and subsequently injected with indicated drugs, 1-hour 702 
post infection. Larvae survival was monitored at the indicated time points by two observers 703 
independently. Each strain/drug combination was evaluated in 4 independent experiments.  704 
 705 
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Cell viability assays and intracellular antibiotic concentration 706 
Ciprofloxacin 707 
Overnight cultures of E. coli BW25113 were diluted 1:1,000 into 50 ml LB and grown at 37°C 708 
to OD595nm ~0.5. Paraquat (50 µg/ml), Vanillin (150 µg/ml), Benzalkonium (5 µg/ml), Caffeine 709 
(200 µg/ml), Doxycycline (0.5 µg/ml), Rifampicin (5 µg/ml), Trimethoprim (5 µg/ml) or 710 
Curcumin (100 µg/ml), were added to the cultures and incubated at 37oC for 30 minutes 711 
prior to the addition of 2.5 µg/ml final concentration ciprofloxacin. The cultures were 712 
incubated at 37oC for 1 hour in the presence of both drugs. Cell viability was determined by 713 
counting CFUs after 16 hours incubation of washed cell pellets plated onto LB agar petri 714 
dishes. Intracellular ciprofloxacin was quantified using liquid chromatography coupled to 715 
tandem mass spectrometry (LC-MS/MS), as previously described 40,41. Non-washed cell 716 
pellets 42 were directly frozen and lysed with 350 µl of acetonitrile, followed by three freeze-717 
thaw cycles (thawing was performed in an ultrasonic bath for 5 min). Cell debris was pelleted 718 
at 16,000 g and the supernatant was filtered through a 0.22 µm syringe filter prior to 719 
injection. Chromatographic separation was achieved on a Waters BEH C18 column (2.1 × 720 
50 mm; 1.7 µm) at 40 °C, with a 2 min gradient with flow rate of 0.5 mL/min: (i) 0–0.5 min, 721 
1% mobile phase B; (ii) 0.5–1.2 min, linear gradient from 1 to 95% mobile phase B; (iii) 1.2–722 
1.6 min, 95% mobile phase B; and (iv) 1.6–1.7 min, return to initial conditions (mobile phase 723 
A consisted of 0.1% formic acid in water, and mobile phase B consisted of 0.1% formic acid 724 
in acetonitrile). Samples were kept at 4 °C until analysis. Sample injection volume was 5 µL. 725 
Detection of ciprofloxacin was performed on a Waters Q-Tof premier instrument with 726 
electrospray ionization in positive mode. The transition 332>314 was monitored, with cone 727 
voltage set at 8 and collision energy set at 20. Intracellular ciprofloxacin was normalized to 728 
CFU at the time of ciprofloxacin addition. 729 
 730 
Gentamicin 731 
Intracellular gentamicin was quantified by measuring [3H]-gentamicin (1 mCi/ml; Hartmann 732 
Analytic Corp.), as previously described 7. Overnight cultures of E. coli MG1655 (the parental 733 
strain of BW25113) were diluted 1:100 into 5 ml LB and grown to OD595nm ~0.1. [3H]-734 
gentamicin was diluted in cold gentamicin to obtain a 5 mg/ml (0,1 mCi/ml) stock solution, 735 
which was then added to the culture at a final concentration of 5 µg/ml (0,1 µCi/ml) together 736 
with the second drug: Berberine (200 µg/ml), Erythromycin (15 µg/ml), Metformin (13000 737 
µg/ml), Procaine (6000 µg/ml), Loperamide (400 µg/ml), Benzalkonium (5 µg/ml), Rifampicin 738 
(5 µg/ml) or Clindamycin (200 µg/ml). Cultures were then incubated at 37°C on a rotary 739 
shaker. At 0, 0.5, 1, 1.5 and 2h time-points, 500 µl aliquots were removed and applied to a 740 
0.45 µm-pore-size HAWP membrane filter (Millipore) pretreated with 1 ml of unlabeled 741 
gentamicin (250 µg/ml). Filters were washed with 10 ml of 1.5% NaCl, placed into counting 742 
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vials, and dried for 30 min at 52°C. 8 ml of liquid scintillation were then added to the dried 743 
filters and vials were incubated overnight at room temperature before being counted for 5 744 
min. Gentamicin uptake efficiency is expressed as total accumulation of gentamicin (ng) per 745 
108 cells, and plotted here for the final time point (2h). Cell viability was determined by 746 
CFUs. 747 
 748 
Spectinomycin 749 
Intracellular spectinomycin was quantified by measuring [3H]-spectinomycin (1 µCi/mg; 750 
Hartmann Analytic Corp.). Overnight cultures of E. coli BW25113 were diluted 1:1,000 into 1 751 
ml LB with and without vanillin (150 µg/ml) and grown to OD595nm ~0.5. 50 µg/ml [3H]-752 
spectinomycin:spectinomycin 1:100 was added and the cultures were incubated for 1 h. 753 
Cultures were pelleted, washed twice with PBS with 50 µg/ml non-labeled spectinomycin, re-754 
suspended in 1% SDS and incubated for 20 min at 85°C. The lysate was mixed with 8 ml 755 
liquid scintillation (Perkin Elmer ULTIMA Gold) and counted for 1 min using a Perkin Elmer 756 
Tri-Carb 2800TR. Measured radioactivity was normalized to cell number as measured by 757 
OD595nm. 758 
 759 
RNA isolation, cDNA preparation and Quantitative RT-PCR 760 
Overnight cultures of E. coli BW25113 and the marR deletion mutant (ΔmarR) were diluted 761 
1:2,000 into 20 ml LB and grown at 37°C to OD595nm ~0.2. Aspirin or vanillin were added to 762 
the cultures to 500 and 150 µg/ml final concentration, respectively (DMSO was added in the 763 
control), followed by a 30 min incubation period at 37°C with agitation. Cells were harvested 764 
and RNA was extracted using the RNeasy Protect Bacteria Mini Kit (Qiagen). cDNA was 765 
prepared for qRT-PCR using SuperScript™ III Reverse Transcriptase (Thermo Fisher 766 
Scientific). marA expression levels were estimated by quantitative RT-PCR using SYBR™ 767 
Green PCR master mix following the manufacturer's instructions (Thermo Fisher Scientific). 768 
Primer sequences for marA and recA were previously described 29. All experiments were 769 
conducted in at least three biological replicates, and relative expression levels were 770 
estimated according to Livak et al. 43, using recA expression as reference. 771 
 772 
Immunoblot analysis for protein quantification 773 
Overnight cultures of E. coli BW25113 and the marA deletion mutant (ΔmarA) were diluted 774 
1:1,000 into 50 ml LB containing 500 µg/ml aspirin, 150 µg/ml vanillin or DMSO (solvent 775 
control), followed by growth with agitation at 37°C to OD595nm ~0.5. Cells were washed in 776 
PBS containing corresponding drugs or DMSO, then resuspended to match OD595nm = 1. 777 
Cell pellets were resuspended in Laemmli buffer and heated to 95°C for 3 minutes followed 778 
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by immunoblot analysis with α-AcrA polyclonal antiserum (gift from K.M. Pos) at 1:200,000 779 
dilution. Primary antiserum was detected using anti-rabbit HRP (A0545 Sigma) at 1:5,000 780 
dilution. Cell loading was controlled with the anti-RecA antibody (rabbit, ab63797 Abcam). 781 
For densitometry analysis, pixel intensity of AcrA bands from cell density normalised 782 
samples were quantified using ImageJ. At least four different biological replicates were 783 
blotted and summarized by their mean and standard deviation. Each biological replicate was 784 
run and blotted twice (technical replicates). Relative AcrA levels per biological replicate 785 
correspond to the average intensities of the technical replicates. All blots can be seen in 786 
Supplementary Fig. 1. 787 
 788 
Screening the E. coli Keio Knockout Collection for identifying MoA of drug 789 
interactions 790 
The E. coli Keio Knockout Collection 26 (two independent clones per mutant) was arrayed in 791 
1536-format in LB agar plates using a Rotor HDA (Singer Instruments) as previously 792 
described 29. The growth of each mutant was estimated by colony opacity 44 after 13 hours 793 
incubation at 37oC in the absence and presence of vanillin (200 µg/ml), spectinomycin (4 794 
µg/ml), and their combination. All plates were imaged under controlled lighting conditions 795 
(spImager S&P Robotics) using an 18-megapixel Canon Rebel T3i (Canon). Experiments 796 
were done in biological triplicates. Fitness of each mutant was calculating by dividing the 797 
growth in condition (vanillin, spectinomycin or both) by the growth in LB, after correcting for 798 
outer-frame plate effects 44. Bliss scores were calculated as per Eq. 1 per replicate and then 799 
averaged (Supplementary Table 7) 800 
 801 
Data availability statement 802 
All data supporting the findings of this study are included in this article as supplementary 803 
files.  804 
 805 
Code availability 806 
The code used for data analysis is available from 807 
https://git.embl.de/brochado/combinations_gram_negatives. 808 
 809 
 810 
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Extended Data Figures Legends 811 
Extended Data Figure 1: High-throughput profiling of pairwise drug combinations in 812 
Gram-negative bacteria. a) Drug and species selection for screen. The 79 drugs used in 813 
the combinatorial screen are grouped to categories (Supplementary Table 1). Antibacterials 814 
are grouped by target with the exception of antibiotic classes for which enough 815 
representatives were screened (>2) to form a separate category: β-lactams, macrolides, 816 
tetracyclines, fluoroquinolones and aminoglycosides. Classification of human-targeted drugs 817 
and food additives is not further refined, because the MoA is unclear for most. A subset of 818 
62 arrayed drugs was profiled against the complete set of 79 drugs in 6 strains. Strains are 819 
color coded according to species. Strain colors and abbreviations are used in all main and 820 
ED figures. b) Quantification of drug-drug interactions. Growth was profiled by measuring 821 
optical density (OD595nm) over time in the presence of no, single and both drugs. Interactions 822 
were defined according to Bliss independence. Significantly lower or higher fitness than 823 
expectation (fa*fq) indicates synergy or antagonism, respectively. Synergy and antagonism 824 
were assessed by growth in 4x4 checkerboards (Methods).  825 
 826 
Extended Data Figure 2: Data analysis pipeline. a) Flowchart of the data analysis 827 
pipeline. b) Estimating single drug fitness of arrayed drugs. As drug-drug interactions are 828 
rare, the slope of the line of best fit between gaq (growth with double drug) and gq (growth 829 
with query drug alone – deduced from average of the top 5% growing wells across plates 830 
within a batch) across np query drugs (plates) corresponds to a proxy of the fitness of the 831 
arrayed drug alone, fa (Methods, Eq 3). R denotes the Pearson correlation coefficient 832 
between gaq and gq across np plates. Well A9 from E. coli BW25113 containing 3µg/ml 833 
spectinomycin is shown as an example of arrayed drugs with several interactions; several 834 
query drugs (plates) deviate from the expected fitness (light grey points), therefore only half 835 
of the plates corresponding to the interquartile range of gag/gq were used to estimate fa. c) 836 
Density distributions of quartiles 1, 2 and 3 of Bliss scores (𝜀) distributions for E. coli.  Q1, 837 
Q2 and Q3 denote the median of quartiles 1, 2 and 3 of 𝜀 distributions, respectively. n 838 
denotes the number of drug combinations used.  839 
 840 
Extended Data Figure 3: Data quality control. a) High replicate correlation for single and 841 
double drug treatments. Transparent boxplots contain Pearson correlation coefficients 842 
between plates of the same batch containing arrayed drugs only (LB was used instead of the 843 
second drug). n represents the total number of correlations. Full boxplots contain Pearson 844 
correlation coefficients between double drug replicate wells within the same plate, across all 845 
plates. n represents the number of wells used for correlation, nmax = (62 drugs + 1 LB) x 3 846 
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concentrations = 189. Only wells with median growth above 0.1 were taken into account for 847 
this correlation analysis (see panel b). For all box plots the center line, limits, whiskers and 848 
points correspond to the median, upper and lower quartiles, 1.5x IQR and outliers, 849 
respectively. b) Wells with lower median growth have lower replicate correlation. The double 850 
drug correlation coefficients used to generate the boxplot from a are plotted as a function of 851 
the median growth of all wells across all plates for E. coli iAi1. Wells with overall lower 852 
growth (due to strong inhibition of arrayed drug) are less reproducible due to a combination 853 
of the lower spread of growth values and the sigmoidal nature of the drug dose response 854 
curves. c) Drug-drug interactions are rare. Density distributions of all Bliss scores (𝜀) 855 
obtained per strain. d) The ability to detect synergies and antagonisms depends on the 856 
effects of single drug treatments. Bliss scores (𝜀) are plotted as function of expected fitness 857 
(fa*fq) for all drug concentration ratios for all combinations in E. coli BW (example). Boxplots 858 
summarizing both variables are shown besides the axes (n=99,907 Bliss scores, center line, 859 
limits, whiskers and points correspond to the median, upper and lower quartiles, 1.5x IQR 860 
and outliers, respectively). Blind spots for detecting antagonism and synergy are indicated; 861 
they are both based on the expected fitness (see also ED Fig. 4c-d) and thus dependent on 862 
the growth of the strain with the single drugs. The number of drug combinations falling in the 863 
blind spot for antagonism is larger, due to the number of drugs used in the screen that do 864 
not inhibit E. coli on their own. e) Scatter plot of number of interactions per drug versus the 865 
minimum fitness of the drug alone (as obtained in screen, Supplementary Table 1). Strong 866 
and weak interactions are represented. n denotes the total number of interactions and R is 867 
the Pearson correlation coefficient. Strains are color coded as above. f) Density distributions 868 
of the number of interactions per drug for all strains.  869 
 870 
Extended Data Figure 4: Benchmarking & sensitivity analysis. a) Validation set is 871 
enriched in synergies and antagonisms to assess better true and false positives. 872 
Comparison of the interaction fractions between the screen and validation set. Both strong 873 
and weak interactions (Fig. 2b) are accounted for the screen tally. b) Number of 874 
benchmarked interactions per strain. c & d) Sensitivity analysis of the statistical thresholds 875 
for calling interactions. c) Total amount of interactions as function of the expected fitness 876 
(fa*fb) cutoff used for restricting the 𝜀 distributions to relevant drug concentrations. Strong 877 
drug-drug interactions are classified according to the 𝜀 distribution where they were 878 
significant: complete distribution only (i.e. all expected fitness wells), relevant wells only (i.e. 879 
all wells with fa*fb > cutoff for synergies and all wells with fa*fb < (1-cutoff) for antagonisms), 880 
or in both. Weak drug-drug interactions are independently assigned and represented in 881 
white. We selected an expected fitness cutoff of 0.2, as it resulted in the largest number of 882 
total interactions detected, with the highest precision and recall (91 and 74% respectively) 883 
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after benchmarking against the validation dataset. d) Receiver operating characteristic 884 
(ROC) curve for the screen across different p-value thresholds (two-sided permutation test 885 
of Wilcoxon rank-sum) as a unique criterion for assigning interactions. The selected p-value 886 
(0.05) for screen threshold is indicated by a grey cross. Sensitivity to additional parameters 887 
for calling hits is shown: allowing interactions to be either antagonisms or synergies but not 888 
both (1-sided); strong and weak interaction thresholds. True and false positive rates were 889 
estimated based on the validation dataset. Precision and recall for the final and best 890 
performing set of parameters are shown: one-sided interactions, p < 0.05, fa*fb cutoff = 0.2 891 
and |𝜀|>0.1 for strong interactions, |𝜀| > 0.06 for weak interactions. TP, TN, FP and FN stand 892 
for True Positives, True Negatives, False Positives and False Negatives, respectively. n 893 
indicates the total number of benchmarked drug combinations (Supplementary Table 3). e) 894 
Synergies between β-lactams according to Loewe additivity interaction model. The results of 895 
8x8 checkerboards for 3 combinations between β-lactams in 4 strains are shown. The grey 896 
line in each plot represents null hypothesis in the Loewe additivity model, whereas the black 897 
line corresponds to the IC50 isobole, estimated by fitting a logistic curve to the interpolated 898 
drug concentrations (colored dots, Methods). Piperacillin did not reach 50% growth inhibition 899 
in E. coli, thus IC20 and IC40 isoboles were used for the amoxicillin + piperacillin combination 900 
in E. coli BW and E. coli iAi1, respectively. 901 
 902 
Extended Data Figure 5: Benchmarking of non-comparable drug-drug interactions. a) 903 
The barplot illustrates the division of benchmarked drug combinations according to their 904 
degree of conservation within species. The pie chart shows the proportion of False & True 905 
Positive (FP & TP) and False and True Negatives (FN & TN) within non-comparable drug-906 
drug interactions. b) Combination of amoxicillin with cefotaxime in P. aeruginosa: an 907 
example of a non-comparable drug-drug interaction. The results of the screen are presented 908 
on the upper box. Bliss scores as function of expected fitness for both strains are presented 909 
on the left hand side, while a density distribution of the Bliss scores is shown on the right 910 
hand side. n denotes the total number of Bliss scores, Q1 and Q3 indicate the Bliss score for 911 
quartiles 1 and 3, respectively. Antagonism was detected only for PAO1 (Q3 > 0.1). PA14 912 
was resistant to both drugs at concentrations screened (upper left panel), rendering the 913 
detection of antagonism impossible. The benchmarking results indicate that interaction is 914 
antagonistic in both strains (lower box), albeit weaker at PA14 and visible mostly at higher 915 
concentrations. Color on checkerboard reflects fitness and black dots correspond to drug-916 
ratios where the Bliss score is above 0.1. 917 
 918 
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Extended Data Figure 6: Benchmarking of weak conserved drug-drug interactions. a) 919 
The barplot illustrates the division of benchmarked drug combinations as in ED Fig. 5a. The 920 
pie chart shows the proportion False Positives (FP) and True Positives (TP) within weak 921 
conserved interactions. b) Combination of doxycycline with amikacin in S. Typhimurium: an 922 
example of a weak conserved drug-drug interaction. The results of the screen are presented 923 
on the upper box. Bliss scores as function of expected fitness for both strains are presented 924 
on the left hand side, while a density distribution of the Bliss scores is shown on the right 925 
hand side. n denotes the total number of Bliss scores, Q1 and Q3 indicate the Bliss score for 926 
quartiles 1 and 3, respectively. A strong synergy was detected only for ST14028 (Q1 < -0.1), 927 
and then a weak conserved synergy was assigned afterwards to ST LT2 (Q1 < -0.06). The 928 
benchmarking results, presented on the box below, confirm that the interaction is synergistic 929 
in both strains. Color on checkerboard reflects fitness and black dots correspond to drug-930 
ratios where the Bliss score is below -0.1. 931 
 932 
Extended Data Figure 7: Salmonella and Pseudomonas drug-drug interaction 933 
networks. a & b) Drug category interaction networks. Nodes represent drug categories 934 
according to ED Fig. 1a, and plotted as in Fig. 1b. Conserved interactions, including weak 935 
conserved, are shown here. One of the most well-known and broadly used synergies is that 936 
of aminoglycosides and β-lactams 45. Consistent with its use against P. aeruginosa in clinics, 937 
we detected multiple strong synergies between specific members of the two antibiotic 938 
classes in P. aeruginosa, but fewer interactions in the other two species. c & d) Drug-drug 939 
interactions across cellular processes. Representation as in a & b, but drug categories 940 
targeting the same general cellular process are grouped here. e) Quantification of synergy 941 
and antagonism in the networks from a & b, and the corresponding Chi-squared test p-942 
value. As in E. coli, antagonism occurs more frequently than synergy and almost exclusively 943 
between drugs belonging to different categories in S. Typhimurium and P. aeruginosa. In P. 944 
aeruginosa, there are very few interactions occurring between drugs of the same category.  945 
 946 
Extended Data Figure 8: Drug antagonisms are often due to decrease in intracellular 947 
drug concentrations. a) Cartoon of possible MoAs for drug-drug interactions that function 948 
via modulation of the intracellular drug concentration. A drug (antagonist; blue) inhibits the 949 
uptake or promotes the efflux of another one (black), and thus decreases its intracellular 950 
concentration. b) Different antagonists (see methods for concentrations) of gentamicin (red – 951 
5 µg/ml) and ciprofloxacin (gold – 2.5 µg/ml) identified in our screen for E. coli BW also 952 
rescue the killing effect of the two bactericidal drugs in the same strain or its parental 953 
MG1655 (top right and top left panel, respectively). With the exception of clindamycin (for 954 
gentamicin) and curcumin (for ciprofloxacin) all other antagonists decrease the intracellular 955 
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concentration of their interacting drug (bottom panels) – gentamicin detected by using 956 
radiolabeled compound and ciprofloxacin with LC-MS/MS (Methods). The degree of rescue 957 
(upper panel) in many cases follows the decrease of intracellular concentration (lower 958 
panel), implying that most of these interactions depend at least partially on modulating the 959 
intracellular concentration of the antagonized drug. c) Antagonisms are resolved in E. coli 960 
BW mutants lacking key components controlling the intracellular concentration of the 961 
antagonized drug. Aminoglycosides depend on PMF-energized uptake and thus respiratory 962 
complexes 7,46; ciprofloxacin is effluxed by AcrAB-TolC 29,47. For gentamicin, most 963 
interactions are resolved when respiration is defected, even the one with clindamycin (not 964 
modulating intracellular gentamicin concentration- panel b) presumably because MoA and 965 
import of aminoglycosides are linked in a positive feedback loop 7,48. For ciprofloxacin, 966 
antagonisms with paraquat and caffeine are resolved in the ΔacrA mutant, implying that both 967 
compounds induce the AcrAB-TolC pump (known for paraquat). In contrast, interactions with 968 
curcumin, benzalkonium and doxycycline remain largely intact in the ΔacrA mutant. The first 969 
interaction is expected as curcumin does not modulate intracellular ciprofloxacin 970 
concentration (see panel b). In the other two cases, other component(s) besides AcrAB-971 
TolC may be responsible for the altered ciprofloxacin import/export; for example, 972 
ciprofloxacin uses OmpF to enter the cell 49. Ciprofloxacin and gentamicin concentrations 973 
were adjusted in all strains according to MIC (70% and 100% MIC for ciprofloxacin and 974 
gentamicin, respectively; all drug concentrations are listed in Supplementary Table 6). Bliss 975 
interaction scores (𝜀) were calculated as in screen. Barplots and error bars in c & d 976 
represent the average and standard deviation, respectively, across n independent biological 977 
replicates. d) Gentamicin and ciprofloxacin antagonism networks for E. coli BW. Nodes 978 
represent drugs colored according to targeted cellular process (as ED Fig. 1a). Full and 979 
dashed edges represent antagonistic drug-drug interactions for which intracellular antibiotic 980 
concentration was and was not measured, respectively. Drug interactions that result in 981 
decreased intracellular concentration of the antagonized drug are represented by black 982 
edges. e) Quantification of antagonistic drug-drug interactions from the networks in (d). The 983 
bars for fluoroquinolones and aminoglycosides account for an extrapolation of antagonistic 984 
interactions to all other members of the two classes, assuming they behave the same as 985 
ciprofloxacin and gentamicin, respectively. 986 
 987 
Extended Data Figure 9: Drug-drug interactions are largely conserved within species 988 
and only partially MoA-driven. a & b) Drug-drug interactions are conserved in S. 989 
Typhimurium (a) and P. aeruginosa (b). Scatter plot of interaction scores in the two strains of 990 
each species; only significant interactions for at least one strain are shown. Colors and 991 
grouping as in Fig. 2a. R denotes the Pearson correlation and n the total number 992 
 29 
interactions plotted. Lower correlation in P. aeruginosa is presumably due to fewer and 993 
weaker interactions in total. c) Drug interaction profiles are phylogeny-driven. Clustering of 994 
strains based on Pearson correlation of their drug interaction profiles (taking into account all 995 
pairwise drug combinations; n=2759-2883, depending on the species). Strains of the same 996 
species cluster together, with the two enterobacterial species, E. coli and S. Typhimurium, 997 
behaving more similar to each other than to the phylogenetically more distant P. aeruginosa. 998 
d) Conserved drug-drug interaction network. Nodes represent individual drugs grouped and 999 
colored by targeted cellular process (as in ED Fig. 1a). Drug names are represented by 3 1000 
letter codes (Supplementary Table 1). Dashed and full edges correspond to conserved 1001 
interactions between two or three species, respectively. Many of the human-targeted drugs, 1002 
such as loperamide, verapamil and procaine exhibit a general potentiating effect, similar to 1003 
that of membrane-targeting drugs. This suggests that they may also facilitate drug uptake or 1004 
impair efflux, consistent with previous reports on the role of loperamide in E. coli and 1005 
verapamil in Mycobacterium tuberculosis 4,50. e) Monochromaticity between all drug 1006 
categories. The monochromaticity index (MI) reflects whether interactions between drugs of 1007 
two categories are more synergistic (MI=-1) or antagonistic (MI=1) than the background 1008 
proportion of synergy and antagonism. MI equals zero when interactions between two drug 1009 
categories have the same proportion of synergy and antagonism as all interactions together. 1010 
(Methods). MI was calculated using all interactions from the 6 strains for all category pairs 1011 
that had at least 2 interactions. White cells in the heat map correspond to category pairs for 1012 
which no (or an insufficient number of) interactions were observed. f) Human-targeted drugs, 1013 
and LPS or PMF inhibitors are strong and promiscuous adjuvants. Density distributions of 1014 
the MIs per drug category from panel e are shown. n denotes the amount of drugs in 1015 
category involved in i interactions. 1016 
 1017 
Extended Data Figure 10: Hierarchical clustering of drugs according to their 1018 
interaction profiles. Rows depict the 75 drugs common to all strains (colored according to 1019 
drug category – ED Fig. 1a), and columns account for their interactions with other drugs in 1020 
all six strains tested. Clustering was done using the median of the 𝜀 distributions, uncentered 1021 
correlation and average linkage. 1022 
 1023 
Extended Data Figure 11: Active synergies against Gram-negative MDR clinical 1024 
isolates in vitro and in G. mellonella infection model. Both human-targeted drugs (lately 1025 
found to have an extended impact on bacteria 51) and food additives can promote the action 1026 
of antibiotics in MDR strains, indicating that their use as antibacterial adjuvants should be 1027 
explored further in the future. a) Drug combinations active against MDR E. coli and K. 1028 
pneumoniae clinical isolates (related to Fig. 4). Interactions are shown as 8x8 1029 
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checkerboards and synergies have a black bold border. Drug pairs are the same per line 1030 
and indicated at the first checkerboard. The species in which the interaction was detected in 1031 
the screen are indicated after the last checkerboard. Concentrations increase on equal steps 1032 
per drug (see legend); only minimal and maximal concentrations are shown for the first 1033 
strain of each species. Apart from colistin, the same concentration ranges were used for all 1034 
E. coli and K. pneumoniae MDR strains. One of two replicates is shown. b) Drug synergies 1035 
against the same MDR strains in the Galleria mellonella infection model. Larvae were 1036 
infected by E. coli and K. pneumoniae MDR isolates (106 and 104 CFU, respectively) and left 1037 
untreated, or treated with single drugs or in combination. % larvae survival was monitored at 1038 
indicated intervals after infection – n=10 larvae per treatment. The averages of 4 biological 1039 
replicates are plotted; error bars depict standard deviation.  1040 
 1041 
 1042 
Extended Data Figure 12: Mode of Action for the vanillin-spectinomycin synergy. a) 1043 
Spectinomycin MIC decreases upon addition of 100 µg/ml vanillin in the wildtype E. coli BW, 1044 
as well as single-gene knockouts of members of the AcrAB-TolC efflux pump or its MarA 1045 
regulator. Thus, the vanillin-spectinomycin synergy is independent of the effect of vanillin on 1046 
AcrAB-TolC (Fig. 3). b) Synergy is specific to vanillin-spectinomycin, as spectinomycin is 1047 
antagonized by 500 µg/ml of the vanillin-related compound, aspirin, thereby increasing the 1048 
MIC ~3-fold. c) Profiling the vanillin-spectinomycin combination in the E. coli BW Keio 1049 
collection 26 to deconvolute its MoA. Violin plots of the drug-drug interaction scores 𝜀 of all 1050 
mutants (n=9216; Methods) are presented for the vanillin-spectinomycin combination 1051 
(synergy) and as control, for the combination of vanillin with another aminoglycoside, 1052 
amikacin (antagonism). The interaction scores of the two mdfA deletion clones present in the 1053 
Keio library are indicated by red dots. The vanillin-spectinomycin synergy is lost in the 1054 
absence of mdfA, whereas the vanillin-amikacin antagonism remains unaffected, indicating 1055 
that the vanillin-spectinomycin synergy depends specifically on MdfA. d) Deletion of mdfA 1056 
leads to increased spectinomycin MIC and abolishes the synergy with vanillin, independent 1057 
of the presence or absence of AcrAB-TolC. Mild overexpression of mdfA from a plasmid 1058 
(pmdfA - methods) further enhances the synergy with vanillin, decreasing the spectinomycin 1059 
MIC by ~2-fold (compared to the MIC of the combination in the wildtype). Thus, MdfA levels 1060 
are directly correlated to the degree of the spectinomycin-vanillin synergy. e) 1061 
Overexpression of mdfA leads to increased spectinomycin sensitivity, even though MIC does 1062 
not change. The growth of E. coli BW and pmdfA was measured (OD595nm after 8h) over 2-1063 
fold serial dilutions of spectinomycin and normalized to the no-drug growth of the 1064 
corresponding strain (white and black dots represent the average of n=3 independent 1065 
biological replicates, error bars represent standard deviation). Spectinomycin dose response 1066 
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was computed using a logistic fit of the averaged data points (MICs are calculated by fitting 1067 
individual replicates first and then averaging). Fitted curves are represented by full and 1068 
dashed lines for pmdfA and E. coli BW respectively. f) Vanillin leads to accumulation of 1069 
spectinomycin in the cell in an mdfA-dependent manner. Intracellular spectinomycin is 1070 
measured with the tritiated compound (Methods). Barplots and error bars in a, b, d & f 1071 
represent the average and standard deviation, respectively, across n independent biological 1072 
replicates. 1073 
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